Lumos Diagnostics Holdings Ltd. · ASX:LDX
Lumos Diagnostics — H1 2025 Earnings Presentation
9 slides from Lumos Diagnostics's earnings presentation, Mar 3, 2025
Slide 1: 1H FY25 Investor Briefing
For personal use only Lumos Diagnostics Holdings Limited 1H FY25 Investor Briefing 3 March 2025 Financial information is shown in USD unless otherwise stated. lumosdiagnostics.com 1
Slide 2: Disclaimer and Important Information
Disclaimer and Important Information This presentation (Presentation) has been prepared solely for informational purposes by Lumos Diagnostics Holdings Limited (Company). The information contained in this document (“Document”) has been prepared by Lumos Diagnostics Holdings Limited (referred to as “
Slide 3: Key Highlights – 1H FY25
For personal use only Key Highlights – 1H FY25
Slide 4: Key Highlights – 1H FY25
Key Highlights – 1H FY25 For personal use only Revenue of $6.3 million for the half-year, up 128% compared to PCP (1H FY24 - $2.8 million) Product revenue was up 227% and Services revenue was up 118%. Gross Profit margin was a healthy 67%, an improvement of 12 percentage points over the PCP Adjusted
Slide 5: Profit & Loss Summary
Profit & Loss Summary Strong revenue growth and EBITDA improvement (US$ in thousands) Six months ended 31 Dec 1H FY25 1H FY24 % Change ▪ Revenue: For personal use only o Total revenue $6.3m (+128%) Services revenue 5,468 2,510 +118% o Services revenue $5.5m (+118%) - Positive impact from Products re
Slide 6: Balance Sheet Summary
Balance Sheet Summary Improved net asset position (US$ in thousands) Period ending 31 Dec 30 Jun +/- For personal use only 2024 2024 ▪ Inventory mainly raw materials for ViraDx ahead of US flu season Assets Cash 5,532 6,479 -947 ▪ Trade & Other Receivables includes BARDA receivable of Inventories 1,
Slide 7: Cashflow Summary
Cashflow Summary Closing cash $5.5m - well supported capital raise (US$ in thousands) Six months ended 31 Dec 1H FY25 1H FY24 +/- ▪ Receipts from customers at $3.0m, is lower than revenue reported For personal use only mainly due to recognising revenue on Hologic IP agreement (cash Receipts from cus
Slide 8: Key Priorities
Key Priorities For personal use only Implement bacterial positive enrichment strategy for FebriDx CLIA waiver trial to speed up the study FDA pre-submission for FebriDx pediatric study in April 2025 Continue to drive FebriDx product awareness and sales into US urgent care centers Deliver on Hologic
Slide 9: For personal use only
For personal use only www.lumosdiagnostics.com 9
Lumos Diagnostics Holdings — H1 2025 Earnings Presentation on 6ix